AP2000001959A0 - Treatment of generalized anxiety disorder with paroxetine. - Google Patents

Treatment of generalized anxiety disorder with paroxetine.

Info

Publication number
AP2000001959A0
AP2000001959A0 APAP/P/2000/001959A AP2000001959A AP2000001959A0 AP 2000001959 A0 AP2000001959 A0 AP 2000001959A0 AP 2000001959 A AP2000001959 A AP 2000001959A AP 2000001959 A0 AP2000001959 A0 AP 2000001959A0
Authority
AP
ARIPO
Prior art keywords
paroxetine
treatment
anxiety disorder
generalized anxiety
human
Prior art date
Application number
APAP/P/2000/001959A
Other languages
English (en)
Inventor
Rocco Zaninelli
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of AP2000001959A0 publication Critical patent/AP2000001959A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/2000/001959A 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine. AP2000001959A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808479.1A GB9808479D0 (en) 1998-04-22 1998-04-22 Method of treatment
PCT/US1999/008786 WO1999053919A1 (fr) 1998-04-22 1999-04-22 Traitement de trouble anxieux generalise avec de la paroxetine

Publications (1)

Publication Number Publication Date
AP2000001959A0 true AP2000001959A0 (en) 2000-12-31

Family

ID=10830715

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001959A AP2000001959A0 (en) 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine.

Country Status (20)

Country Link
EP (1) EP1073437A4 (fr)
JP (1) JP2002512189A (fr)
KR (1) KR20010034817A (fr)
CN (1) CN1298301A (fr)
AP (1) AP2000001959A0 (fr)
AU (1) AU3864899A (fr)
BG (1) BG104939A (fr)
BR (1) BR9909791A (fr)
CA (1) CA2328896A1 (fr)
CZ (1) CZ20003885A3 (fr)
EA (1) EA200001088A1 (fr)
GB (1) GB9808479D0 (fr)
HU (1) HUP0101350A3 (fr)
ID (1) ID27546A (fr)
IL (1) IL139167A0 (fr)
NO (1) NO20005286L (fr)
PL (1) PL343494A1 (fr)
SK (1) SK15672000A3 (fr)
TR (1) TR200003082T2 (fr)
WO (1) WO1999053919A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
CN1298301A (zh) 2001-06-06
BG104939A (bg) 2001-09-28
ID27546A (id) 2001-04-12
CA2328896A1 (fr) 1999-10-28
BR9909791A (pt) 2000-12-26
EP1073437A1 (fr) 2001-02-07
JP2002512189A (ja) 2002-04-23
NO20005286D0 (no) 2000-10-20
PL343494A1 (en) 2001-08-27
WO1999053919A1 (fr) 1999-10-28
SK15672000A3 (sk) 2001-04-09
TR200003082T2 (tr) 2001-01-22
KR20010034817A (ko) 2001-04-25
GB9808479D0 (en) 1998-06-17
NO20005286L (no) 2000-12-20
HUP0101350A3 (en) 2002-06-28
EA200001088A1 (ru) 2001-04-23
EP1073437A4 (fr) 2003-04-16
AU3864899A (en) 1999-11-08
HUP0101350A2 (hu) 2002-05-29
IL139167A0 (en) 2001-11-25
CZ20003885A3 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
TW200505901A (en) Muscarinic agonists
BR0009776A (pt) Método de tratamento
ATE92319T1 (de) Piperidinderivat zur schmerzbehandlung.
AU2003219107A8 (en) Tuberculosis treatment using pleuromutilin derivatives
DK0998287T3 (da) Anvendelse af levobupivacain
BG106118A (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
EA199800866A1 (ru) Способ снятия боли
AP2000001959A0 (en) Treatment of generalized anxiety disorder with paroxetine.
EA200100041A1 (ru) Способ лечения
BR9811004A (pt) "tratamento e prevenção de distúrbios cardìacos usando inibidores seletivos (ssri) da reelevação do nìvel de serotonina"
TR199500984A2 (tr) Selegilin'in epileptik hastaliklarin tedavisinde kullanimi.
EP0904094A4 (fr) Traitement de maladies osseuses au moyen d'adrenomedulline
HRP20080389A2 (en) THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
UA29302A (uk) Спосіб підвищення відтворної функції сільськогосподарських тварин
UA30458A (uk) Спосіб біологічної кастрації тварин